內(nèi)皮細(xì)胞特異分子1(ESM1)檢測試劑盒(酶聯(lián)免疫吸附試驗法)
ELISA Kit for Endothelial Cell Specific Molecule 1 (ESM1)
Endocan
- 編號SEC463Mu
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長3h
- 檢測范圍7.8-500ng/mL
- 靈敏度最小可檢測劑量小于等于3.1ng/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價格 ¥ 3024 ¥ 4320 ¥ 19440 ¥ 36720 ¥ 302400
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測內(nèi)皮細(xì)胞特異分子1(ESM1),經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測,因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的內(nèi)皮細(xì)胞特異分子1(ESM1)(加標(biāo)樣品),重復(fù)測定并計算其均值,回收率為測定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 95-103 | 98 |
EDTA plasma(n=5) | 98-105 | 101 |
heparin plasma(n=5) | 84-98 | 90 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次,分別計算不同濃度樣本的平均值及SD值。
批間差:選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定,每個樣本使用同一試劑盒重復(fù)測定8次,分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的內(nèi)皮細(xì)胞特異分子1(ESM1),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中內(nèi)皮細(xì)胞特異分子1(ESM1)含量的測定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 91-101% | 83-98% | 80-93% | 80-95% |
EDTA plasma(n=5) | 85-97% | 94-102% | 87-98% | 88-97% |
heparin plasma(n=5) | 85-101% | 98-105% | 94-105% | 97-105% |
穩(wěn)定性
經(jīng)測定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響,實驗室的環(huán)境條件需盡量保持一致,尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品及樣本)100µL,37°C孵育1小時;
3. 吸棄,加檢測溶液A100µL,37°C孵育1小時;
4. 洗板3次;
5. 加檢測溶液B100µL,37°C孵育30分鐘;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分鐘;
8. 加終止液50µL,立即450nm讀數(shù)。
實驗原理
將內(nèi)皮細(xì)胞特異分子1(ESM1)抗體包被于96孔微孔板中,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本,其中的內(nèi)皮細(xì)胞特異分子1(ESM1)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的內(nèi)皮細(xì)胞特異分子1(ESM1)抗體,將未結(jié)合的生物素化抗體洗凈后,加入HRP標(biāo)記的親和素,再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色,并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的內(nèi)皮細(xì)胞特異分子1(ESM1)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值),計算樣品濃度。
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPC463Mu01 | 內(nèi)皮細(xì)胞特異分子1(ESM1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPC463Mu02 | 內(nèi)皮細(xì)胞特異分子1(ESM1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAC463Mu01 | 內(nèi)皮細(xì)胞特異分子1(ESM1)多克隆抗體 | WB; IHC; ICC; IP. |
PAC463Mu02 | 內(nèi)皮細(xì)胞特異分子1(ESM1)多克隆抗體 | WB; IHC; ICC; IP. |
SEC463Mu | 內(nèi)皮細(xì)胞特異分子1(ESM1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
參考文獻
雜志 | 參考文獻 |
Urology | Detection on dynamic changes of endothelial cell specific molecule-1 in acute rejection after renal transplantation [PubMed: 22608803] |
Microvasc Res. | Endocan is useful biomarker of survival and severity in sepsis. [Pubmed: 24769132] |
J Matern Fetal Neonatal Med. | Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes [Pubmed:25211383] |
Microvasc Res. | Endocan is useful biomarker of survival and severity in sepsis [Pubmed:24769132] |
Angiology | Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus [PubMed: 26614790] |
Archives of Medical Science - Atherosclerotic Diseases | Assessment of subclinical cardiac damage in chronic plaque psoriasis patients: a case control study [Journal:-102] |
Int Immunopharmacol.? | Inhibition of endocan attenuates monocrotaline-induced connective tissue disease related pulmonary arterial hypertension. [pubmed:27912147] |
Oncotarget | Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer [pubmed:28514746] |
Biomedical and Pharmacology Journal | Changes in Endocan Levels and Blood Coagulation in HIV Infection [DOI: 10.13005/bpj/1082] |
Life Sciences | A novel role of endocan in alleviating LPS-induced acute lung injury [Pubmed:29627442] |
International Urology and Nephrology | Is the plasma endocan level a reliable predictor for the severity of erectile dysfunction? [Pubmed:30054863] |
The Open Rheumatology Journal | Serum Level of Endothelial Cell-Specific Molecule-1 (ESM-1) as a New Potential Biomarker for Rheumatoid Arthritis Disease Activity [Doi: 10.2174/1874312901812010189] |
Molecular?Medicine?Reports | Downregulation of ENDOCAN in myeloid leukemia cells inhibits proliferation and promotes apoptosis by suppressing nuclear factor?κB activity [Pubmed: 30816462] |
Biomarkers in Medicine | Endothelial biomarkers in the light of new sepsis definition [Pubmed: 30920847] |
Experimental and Therapeutic Medicine | Risk stratification and prognostic evaluation of endothelial cell?specific molecule1, von Willebrand factor, and a disintegrin?like and metalloprotease with?… [] |
Turkish Journal of Medical Sciences | A novel marker relationship between carotid intima–media thickness and disease activity score-28 in patients with rheumatoid arthritis: human endothelial cell?… [Pubmed: 31655533] |
Biomarkers | Role of Ascitic Endocan Levels in the Diagnosis of Spontaneous Bacterial Peritonitis in Decompensated Cirrhosis [Pubmed: 32364003] |
J Obstet Gynaecol Res | Comparison of the maternal serum endocan levels in preterm premature rupture of membrane and normal pregnancy [34109715] |
turkish journal clinics laboratory | The relationship between serum endocan levels with the presence of contrast-induced nephropathy in patients undergoing coronary angiography [] |